Company* |
Company* |
Product | Terms/Details (Date) |
Asuragen Inc.* |
Digene Corp. |
Worldwide deal for the marketing and distribution of Asuragen's cystic fibrosis screening products |
Digene gets exclusive rights to market the products, as well as follow-on products; Asuragen gets an up-front payment and potential milestone payments (4/19)# |
CombiMatrix |
Prisma Biotech Corp.* (Taiwan) |
Prisma will promote and sell CombiMatrix products in Taiwan, China and certain other countries |
Prisma also can synthesize content onto CombiMatrix CustomArrays and sell those arrays to end customers; terms were not disclosed (4/28) |
Nabi Bio- |
Inhibitex Inc. |
Inhibitex terminated deal covering the manufacture of its Veronate product |
The move follows a failed Phase III trial of Veronate for preventing hospital-associated infections in premature, very low-birth infants (4/28) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
# Item occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
